Share

April 09, 2019; 92 (15) Article

Immune myopathy with large histiocyte-related myofiber necrosis

Alan Pestronk, Namita Sinha, Ziad Alhumayyd, Cindy Ly, Robert Schmidt, Robert Bucelli
First published March 20, 2019, DOI: https://doi.org/10.1212/WNL.0000000000007260
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
373

Share

Article Information

vol. 92 no. 15 e1763-e1772
DOI: 
https://doi.org/10.1212/WNL.0000000000007260
PubMed: 
30894448
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received March 17, 2018
  • Accepted in final form December 10, 2018
  • First Published March 20, 2019.

Article Versions

Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. Alan Pestronk, MD,
    2. Namita Sinha, MD,
    3. Ziad Alhumayyd, MD,
    4. Cindy Ly, MD,
    5. Robert Schmidt, MD and
    6. Robert Bucelli, MD
  1. Alan Pestronk, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) TS-HDS antibody 7,175,989, issued 2007; (2) GALOP antibody 6,121,004, issued 2000; (3) GM1 ganglioside antibody 6,077,681, issued 2000; (4) Sulfatide antibody 6,020,140, issued 1995 (5) NS6S antibody 9,535,072, issued 2017

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Ionis, (2) Biogen, (3) Idera, (4) Ultragenyx, (5) Acceleron, (6) Cytokinetics, (7) Sanofi, (8) Amicus

    Research Support, Government Entities:

    1. NIH

    Research Support, Academic Entities:

    1. Washington University Neuromuscular Research Fund

    Research Support, Foundations and Societies:

    1. (1) Muscular Dystrophy Association, Clinic Director 1989 - 2019

    Stock/Stock Options/Board of Directors Compensation:

    1. Johnson & Johnson, hold stock

    License fee payments, Technology or Inventions:

    1. Antibody testing, Athena

    Royalty Payments, Technology or Inventions:

    1. (1) GALOP antibody 6,121,004, issued 2000; (2) GM1 ganglioside antibody 6,077,681, issued 2000; (3) Sulfatide antibody 6,020,140; issued 1995

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Namita Sinha, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ziad Alhumayyd, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Cindy Ly, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Dr. Ly receives funding support from NIH K08 NS107621, PI, 2018

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr. Ly received funding support from an American Association of Neurology/ American Brain Foundation/ ALS Association sponsored Clinical Research Training Fellowship

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Robert Schmidt, MD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1) Brain Pathology, Senior Editor 2) Journal of Neuropathology Experimental Neurology, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Robert Bucelli, MD
    7. Scientific Advisory Boards:

    1. I was asked to participate in an advisory board meeting for MT Pharma prior to the launch of edaravone. This was limited to a single meeting and I have no ongoing ties to MT Pharma.

    Gifts:

    1. 1) Parents of a family member I care for with Parsonage Turner syndrome, a recurring annual financial gift has been provided to me in hopes that it could be used towards Parsonage Turner research.

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. I have equity in the Neurology board review website called Neuroquestions, LLC

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Neurology (A.P., C.L., R.B.) and Pathology and Immunology (A.P., N.S., R.S.), Washington University School of Medicine, Saint Louis, MO; and Department of Neurology (Z.A.), King Saud University, Riyadh, Saudi Arabia.
  1. Correspondence
    Dr. Pestronk pestronka{at}neuro.wustl.edu
View Full Text

Article usage

Article usage: March 2019 to March 2021

AbstractFullPdfSource
Mar 2019207024Highwire
Apr 20194442227Highwire
May 20193292321Highwire
Jun 20195302021Highwire
Jul 201910168Highwire
Aug 2019901014Highwire
Sep 201910387Highwire
Oct 2019102119Highwire
Nov 2019128410Highwire
Dec 2019132511Highwire
Jan 2020112411Highwire
Feb 202059615Highwire
Mar 202053214Highwire
Apr 202076913Highwire
May 2020107115Highwire
Jun 202077417Highwire
Jul 202073512Highwire
Aug 202072519Highwire
Sep 202073529Highwire
Oct 202079216Highwire
Nov 202015669Highwire
Dec 202097821Highwire
Jan 20214707Highwire
Feb 202146112Highwire
Mar 202154411Highwire

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me